Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study.

Kausik K RayNafeesa DhalwaniMahendra SibartieIan BridgesChristoph EbenbichlerPasquale Perrone-FilardiGuillermo VillaAnja VogtEric Bruckert

Published in: European heart journal. Quality of care & clinical outcomes (2022)

Across Europe, LDL-C levels at evolocumab initiation were three times higher than recommended thresholds for PCSK9i initiation, reflecting disparities between implementation and guidelines. More patients attained risk-based LDL-C goals when receiving evolocumab in combination with LLT vs. those not receiving combination therapy. Population health could be improved and LDL-C goals better attained if LDL-C thresholds for PCSK9i reimbursement were lowered, enabling more patients to receive combination therapy when needed.

Keyphrases

combination therapy
low density lipoprotein
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
healthcare
primary care
patient reported outcomes